Q-omics provides the consensus-scored LRRC15 profile across patient tissues and cancer cell-line models. LRRC15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LRRC15 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, LRRC15 RNA expression shows 17,242 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, HNSC, and BRCA as cancer lineages where LRRC15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC15 survival associations across molecular data types. LRRC15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC15 RNA expression–survival associations across cancer types. High LRRC15 expression shows unfavorable associations in KIRP, KIRC, LGG and ACC, but favorable associations in DLBC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LRRC15 RNA expression.
This table summarizes LRRC15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LRRC15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC15 shows higher tumor expression in HNSC, LUAD, BLCA, COAD, LUSC and BRCA. The HNSC box plot shows higher LRRC15 RNA expression in tumor versus normal tissue (log2 FC = +2.768, t-test p < 0.001).
This table shows molecular features associated with LRRC15 in patient tissues and cancer cell lines. In patient samples, LRRC15 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
